-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 23, the CDE official website showed that Junshi Runjia’s class 1 new drug RP903 was submitted for clinical application
From: CDE official website
According to the Insight database, the two cooperative projects are the pan-CDK inhibitor JS104 and the PI3Kα inhibitor JS105
Junshi Biology and Runjia Pharmaceutical Cooperation Project
From: Insight Database Global New Drug Module (http://db.
The CDK inhibitor project mainly develops an oral small-molecule CDK inhibitor that can effectively inhibit the activities of various cyclin-dependent protein kinases, including CDK-1, CDK-2, CDK-4, CDK-6, CDK-9,
The PI3K inhibitor project mainly develops an oral small molecule alpha-specific PI3K inhibitor
According to the cooperation agreement between the two parties, the 150 million yuan technology transfer fee for each drug project will be paid in three installments
As one of the partners, Runjia Pharmaceutical Technology and Junshi Biotechnology will share the relevant rights and interests of the two drug projects, including research and development technology, related patent applications (whether granted or not), continuous clinical trials and manufacturing rights after approval and sales rights (or grant manufacturing rights and sales rights in China and worldwide)
Junshi Bio said that the research and development cooperation of small molecule drugs in the field of anti-tumor therapy with Runjia Pharmaceutical Technology will not only complement Junshi Bio’s research and development pipeline of small molecule anti-tumor drugs, but also benefit its own combination of monoclonal antibody drugs.
According to the enterprise analysis module of the Insight database, Junshi Bio has already had 6 new chemical drugs in clinical development in China
Insight Enterprise Analysis: Overview of Junshi Bio's Domestic Products
From: Insight Database Enterprise Analysis Module (http://db.
Among the new chemical drugs, the first clinical application is the PARP inhibitor Senaparib, which has already started Phase III clinical trials
In 2021, Junshi has successively applied for 4 new chemical drugs in cooperation with Weijing Bio, targeting targets such as XPO1, AuroraA and EGFRExon20, all of which are anticancer drug targets with few companies and great potential.
Junshi Bio-Domestic Drug Project
From: Insight database project progress module (http://db.
